Metronidazole News and Research

RSS

Optimer Pharmaceuticals presents additional data from Phase 3 fidaxomicin study

Optimer Pharmaceuticals, Inc. today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia, PA.

2 Nov 2009

Stomach infection on the rise in outpatient settings; symptoms can range from diarrhea to life-threatening inflammation

Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile, (http://www.mayoclinic.org/c-difficile/) is on the rise in outpatient settings.

27 Oct 2009

Ipsen's Azzalure muscle relaxant receives Spanish AEMPS marketing approval

Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.

21 Sep 2009

Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

16 Sep 2009

Recurrence of Clostridium difficile infection is a growing area of concern in hospitals

Arlington Medical Resources (AMR) and Decision Resources find that relapse or recurrence of infections is the most challenging aspect of treating Clostridium difficile infections in the hospital setting.

3 Sep 2009

The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women

Antimicrobial treatments for bacterial vaginosis (BV) are effective, but taking lactobacillus tablets alongside metronidazole antibiotic therapy increases effectiveness over taking this antibiotic alone, according to a Cochrane Systematic Review. The researchers also concluded that intravaginal lactobacillus was as effective as oral metronidazole, although they did note unexplained drop-outs from the trials.

7 Jul 2009

Antibiotics diminish diversity of helpful gutmicrobes

It's common knowledge that a protective navy of bacteria normally floats in our intestinal tracts. Antibiotics at least temporarily disturb the normal balance. But it's unclear which antibiotics are the most disruptive, and if the full array of "good bacteria" return promptly or remain altered for some time.

18 Jun 2009

Why does aspirin increase the susceptibility of Helicobacter pylori to antimicrobials?

Resent studies reported that aspirin inhibited the growth of H. pylori in a dose-dependent manner and significantly affected the activity of virulence factors of H. pylori.

2 Apr 2009

Doctors identify patients at high risk of Clostridium difficile

Doctors have developed and validated a clinical prediction rule for recurrent Clostridium difficile ( C. difficile ) infection that was simple, reliable and accurate, and can be used to identify high-risk patients most likely to benefit from measures to prevent recurrence.

1 Apr 2009

Why does aspirin increase the susceptibility of Helicobacter pylori to antimicrobials?

Resent studies reported that aspirin inhibited the growth of H. pylori in a dose-dependent manner and significantly affected the activity of virulence factors of H. pylori.

3 Mar 2009

Phase 2 trial of treatment of C-difficile-associated diarrhea shows promise

Medarex, Inc. and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti- C. difficile antibody combination treatment in patients with C.

4 Nov 2008

New research into superbug Clostridium difficile

New research into the toxins, virulence, spread and prevention of the superbug Clostridium difficile is reported in the June special issue of the Journal of Medical Microbiology. These findings will play a crucial role in providing us with ammunition in the fight against a sometimes deadly pathogen.

1 Jun 2008

Vaginal probiotic product reduce recurrence rate of bacterial vaginosis

A newly published double blind, randomised, placebo controlled study(1) shows that EcoVag, a patented vaginal probiotic product from the Danish company, Bifodan, significantly reduces the recurrence rate of Bacterial Vaginosis (BV) following antibiotic treatment.

31 Jan 2008

New treatment to combat bowel infection among the elderly

Scientists at the Alimentary Pharmabiotic Centre (APC), based in University College Cork (UCC) and Teagasc’s Moorepark Food Research Centre, are researching a new treatment to combat the increasing incidences of hospital acquired diarrhoea which has become a major problem in hospitals, nursing homes and facilities for the elderly.

1 Aug 2007

FDA approves treatment for bacterial vaginosis

Mission Pharmacal has announced that the U.S. Food and Drug Administration (FDA) approved Tindamax (tinidazole) for the treatment of bacterial vaginosis (BV), the most common vaginal infection among women of childbearing age in the United States.

28 May 2007

New Rosacea treatment kit

Galderma Laboratories, L.P. has announced the availability of a new MetroGel 1% Kit for the topical treatment of the inflammatory lesions of rosacea.

14 Jan 2007

Individualized treatment options for rosacea

Many individuals who are struggling with redness, pimples and visible blood vessels on their face may incorrectly diagnose their condition as acne, sunburn or sensitive skin.

6 Mar 2006

New treatment for rosacea

Galderma Laboratories has announced FDA approval of a new product for the topical treatment of the inflammatory lesions of rosacea. MetroGel (metronidazole) Topical Gel, 1% will be available by prescription July 29, 2005. The new medication incorporates a higher concentration of metronidazole in a new, technologically advanced vehicle.

6 Jul 2005

Superbug possibly the same as US killer strain

Microbiologists at the Health Protection Agency suspect that the superbug which has already caused 12 deaths at Stoke Mandeville Hospital, in Buckinghamshire, may be the same strain that has spread in many American hospitals since 2001, and killed more than 100 patients in Quebec, Canada, last year.

8 Jun 2005

12 deaths creates new infection scare in UK hospitals

There have been some 300 cases of Clostridium difficile in 18 months at Stoke Mandeville Hospital, in Aylesbury, Bucks, a national centre for spinal injury, and it is thought that the infection was an "actual or probable" factor in 12 deaths in that time.

6 Jun 2005